A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females of non-childbearing potential
Genotype 1 chronic hepatitis C
Laboratory evidence of HCV infection for 6 months
Histologic evidence of chronic hepatitis C
Subjects who have a body mass index (BMI) of ≤35 kg/m² (BMI = weight in kg / height² in meters)
Treatment Arm E: This arm will enroll only subjects infected with HCV genotype 1b virus
Treatment Arm F: This arm will enroll only subjects infected with HCV genotype 1a virus
You may not be if
Subjects who have received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C
Subjects with any contraindications to peginterferon alfa-2a and/or ribavirin
Subjects with any other cause of significant liver disease in addition to hepatitis C, which may include, but is not limited to malignancy with hepatic involvement, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis (NASH), or primary biliary cirrhosis
